Overview

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Status:
Completed

Trial end date:
2017-08-14

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, placebo-controlled, 4 part study will assess the safety, tolerability, pharmacokinetics and antiviral activity of orally administered AL-794 in healthy volunteers (HV).

Phase:

Phase 1

Details

Lead Sponsor:

Alios Biopharma Inc.

Treatments:

Antiviral Agents